Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic
  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Leo Pharma Acquires Global Rights to Atopic Dermatitis Treatment in $580 Million Deal

Leo Pharma, a Denmark dermatology company, acquired global rights to a novel treatment for atopic dermatitis (AD) and allergic asthma in an agreement worth up to $570 million. FB825 is a first-in-class candidate that targets the CεmX domain of membrane-bound IgE (mIgE), causing a depletion of mIgE positive B-cells and slowing the immune response, the company said. Leo acquired FB825 from Oneness Biotech of Taiwan and Microbio Shanghai. It made a $40 million upfront payment and will pay up to $530 million of milestones, plus royalties. More details.... Stock Symbol: (TPEx: 4743) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.